1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Oral formulation of Aloxi approved in the US

 
• By Ian Haydock

A new oral capsule formulation of Helsinn Healthcare/Eisai's 5HT3-antagonist Aloxi (palonosetron hydrochloride) has been approved by the US FDA for the prevention of nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5mg capsule is administered around one hour before treatment. A 0.25mg iv formulation of the product has been available in the US since 2003 for the prevention of acute and delayed nausea and vomiting in the same setting and also for prevention of acute nausea and vomiting from initial and repeat courses of highly emetogenic chemotherapy. Eisai acquired North American rights as part of its January purchase of MGI Pharma, which had licensed these from Helsinn. A 0.075mg iv formulation was launched in the US in July for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery.

A new oral capsule formulation of Helsinn Healthcare/Eisai's 5HT3-antagonist Aloxi (palonosetron hydrochloride) has been approved by the US FDA for the prevention of nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5mg capsule is administered around one hour before treatment. A 0.25mg iv formulation of the product has been available in the US since 2003 for the prevention of acute and delayed nausea and vomiting in the same setting and also for prevention of acute nausea and vomiting from initial and repeat courses of highly emetogenic chemotherapy. Eisai acquired North American rights as part of its January purchase of MGI Pharma, which had licensed these from Helsinn. A 0.075mg iv formulation was launched in the US in July for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapeutic Category

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.